GLP-1 medications such as Ozempic and Wegovy are widely praised for their effectiveness in promoting weight loss and improving blood sugar control. But emerging research suggests they may carry unintended consequences.
A large analysis of more than 146,000 adults with obesity and Type 2 diabetes found that people taking GLP-1 drugs had a roughly 30% higher risk of developing osteoporosis compared to nonusers. Rates of gout were also modestly higher, particularly among those experiencing rapid weight loss.
Researchers say the mechanism is not yet fully understood. Rapid weight loss itself is known to contribute to bone loss, and appetite suppression may reduce intake of key nutrients such as calcium, vitamin D, and protein — all critical for maintaining bone density. Some experts also speculate that significant weight reduction changes the mechanical load placed on the skeleton, potentially accelerating bone remodeling in ways that weaken structure over time.
While the study does not prove the drugs directly cause bone loss, it underscores the importance of a comprehensive approach to weight management. Adequate protein intake, resistance training and proper nutrient status may help mitigate potential risks. As GLP-1 use expands beyond diabetes treatment into widespread weight loss therapy, long-term bone health monitoring may become an essential part of patient care.
SOURCE:
NBC News, March 2, 2026